NHS foundation trust

New Blood Test Predicts Recurrence of Breast Cancer, Months or Even Years Before Relapse

Retrieved on: 
Sonntag, Juni 2, 2024
Science, Biotechnology, Research, Surgery, Oncology, Health, Genetics, Clinical Trials, Breast cancer, ASCO, Institute of Cancer Research, NHS foundation trust, Patient, Cell, Ultra, Cancer, The Institute, Exon, Society, DNA, Chief Justice of Hungary, Molecular oncology, MRD, Genome, Sequence, Woman, WES, Recurrence, Risk, Disease, Blood, ICR, Gene, Breast, Diagnosis, Whole genome sequencing, Weapon, Survival, Neoplasm, WGS, Medical imaging

A new type of blood test can predict the recurrence of breast cancer in high-risk patients, months or even years before they relapse, research has shown.

Key Points: 
  • A new type of blood test can predict the recurrence of breast cancer in high-risk patients, months or even years before they relapse, research has shown.
  • Blood samples from 78 patients with different types of early breast cancer (23 with triple negative breast cancer, 35 with HER2+ breast cancer, 18 with hormone receptor+ breast cancer and two with an unknown subtype) were screened for ctDNA.
  • The median lead time to clinical relapse in this group of patients was 15 months, an increase of over three months, compared with other ctDNA tests in all types of breast cancer.
  • The study shows the importance and promise of using an ultra-sensitive MRD test like NeXT Personal to detect the earliest traces of breast cancer recurrence, and more optimally guide management of breast cancer patients.”

Trevi Therapeutics to Participate in Upcoming Conferences

Retrieved on: 
Donnerstag, Mai 9, 2024
Corporation, Idiopathic pulmonary fibrosis, University, NIHR, NHS foundation trust, IPF, Respiratory Medicine, Doctor of Philosophy, MB, Chronic cough, University of Manchester, Panel, RCC, FRCP, Therapy, Management

Corporate Presentation: May 14 at 12:00 p.m.

Key Points: 
  • Corporate Presentation: May 14 at 12:00 p.m.
  • ET
    Presenter: Jacky Smith, MB, ChB, FRCP, PhD, Professor of Respiratory Medicine at the University of Manchester, and an Honorary Consultant at Manchester University NHS Foundation Trust.
  • Director of the NIHR Manchester Clinical Research Facility, Respiratory Theme Lead in the NIHR Manchester Biomedical Research Centre and an NIHR Senior Investigator.
  • Panel Members: Experts in the field of chronic cough include Professor Peter Dicpinigaitis, Professor Jacky Smith, and Professor Alyn Morice.

New Transformative Leadership Team Announced for Texas Children's World-Renowned Heart Center

Retrieved on: 
Freitag, Mai 3, 2024
News, Pediatrics, Surgeon, Doctor of Philosophy, Bachelor of Science, Baylor University, Diagnosis, Texas Children's Hospital, Medical director, University, DRS, Ventricular septal defect, Baylor College of Medicine, Faculty, Moss, Royal Children, National university, Royal college, Executive, Hospital, Research, Monash University, Division, Congenital heart defect, Arrhythmia, Cardiomyopathy, NHS foundation trust, Evelina London Children's Hospital, Patient, Principal, Molecular medicine, Growth, Dentistry

Dr. Daniel Penny , previously Chief of Cardiology at Texas Children's Hospital, was recently named as Executive Co-Director of the Heart Center.

Key Points: 
  • Dr. Daniel Penny , previously Chief of Cardiology at Texas Children's Hospital, was recently named as Executive Co-Director of the Heart Center.
  • "We are incredibly proud to announce our new Heart Center executive leadership team," said Dr. Lara Shekerdemian , Pediatrician-In-Chief and chair of Pediatrics at Texas Children's Hospital.
  • "I am truly honored to join the leadership team at Texas Children's Heart Center," said Dr. Salih.
  • "For many decades now, Texas Children's Heart Center has cared for the world's rarest and most complex heart conditions.

Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference

Retrieved on: 
Dienstag, April 9, 2024
MB, NHS foundation trust, Conference, ATS, NIHR, University of Manchester, University, Doctor of Philosophy, Respiratory Medicine, American Thoracic Society, Chronic cough, FRCP, IPF, Idiopathic pulmonary fibrosis, RCC, Therapy

NEW HAVEN, Conn., April 9, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that data from the Phase 2 CANAL trial will be presented at the American Thoracic Society (ATS) 2024 International Conference being held in San Diego, CA, from May 17-22. The presentation will take place on May 19th.

Key Points: 
  • NEW HAVEN, Conn., April 9, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that data from the Phase 2 CANAL trial will be presented at the American Thoracic Society (ATS) 2024 International Conference being held in San Diego, CA, from May 17-22.
  • The presentation will take place on May 19th.
  • Presenter: Jacky Smith, MB, ChB, FRCP, PhD, Professor of Respiratory Medicine at the University of Manchester, and an Honorary Consultant at Manchester University NHS Foundation Trust.
  • Director of the NIHR Manchester Clinical Research Facility, Respiratory Theme Lead in the NIHR Manchester Biomedical Research Centre and an NIHR Senior Investigator.

Volition appoints Dr Andrew Retter as Chief Medical Officer

Retrieved on: 
Dienstag, März 19, 2024
NHS foundation trust, Thrombosis, Sepsis, Guy, Disease, Neutrophil extracellular traps, Consultant, Patient, Research, Intensive care medicine, Respiratory failure, ECMO, NETS, Cancer, Heart, Nursing care plan, Clinical governance, Nursing

HENDERSON, Nev., March 19, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has appointed Dr Andrew Retter as its Chief Medical Officer, effective April 1, 2024.

Key Points: 
  • HENDERSON, Nev., March 19, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has appointed Dr Andrew Retter as its Chief Medical Officer, effective April 1, 2024.
  • Dr Retter will provide medical leadership at Volition and ensure the company's scientific and clinical efforts are aligned with patient needs.
  • Cameron Reynolds, President and Group Chief Executive Officer at Volition, said: "We are delighted to welcome Andrew to Volition.
  • As Chief Medical Officer he will be vital to our success – ensuring the needs of the patient are placed at the heart of our research, development and commercialization activities."

Aktana Announces Release of Next Generation Omnichannel Orchestration Tools Designed for Medical Technology Companies

Retrieved on: 
Dienstag, März 5, 2024
Technology, Medical Devices, Health Technology, Software, Networks, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Intelligence, NHS foundation trust, Guy, CRM, Medtech, Patient, Research, Sales

“However, less than 20% of MedTech companies are using advanced omnichannel capabilities.

Key Points: 
  • “However, less than 20% of MedTech companies are using advanced omnichannel capabilities.
  • Aktana for MedTech is comprised of Aktana’s world-class open platform, Field Orchestrator, Omnichannel Orchestrator, Analytics Activator, as well as Copilot Mobile.
  • Specifically, Aktana for MedTech:
    Allows medical technology companies to simplify scheduling, manage stock, optimize inventory utilization and streamline procurement processes with AI-powered omnichannel orchestration.
  • Today, commercial and medical teams from more than 350 brands use Aktana’s next generation-AI complete orchestration to deliver personalized omnichannel engagement at scale.

Aleta Biotherapeutics and Cancer Research UK’s Centre for Drug Development Announce First Patient Dosed in ALETA-001 Phase 1/2 Clinical Trial in Patients with Relapsed/Refractory B-Cell Malignancies

Retrieved on: 
Mittwoch, Februar 21, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, CTE, Multimedia, Teaching hospital, Cancer, NHS foundation trust, Drug development, Cancer Research UK, Safety, Bone marrow, Lymphoid leukemia, Patient, Clinical trial, Cancer research

Aleta Biotherapeutics (Aleta), a clinical stage, immuno-oncology company with a CAR T-Cell Engager (CTE) platform that enables cell cancer therapies to work more effectively, and Cancer Research UK’s Centre for Drug Development, today announce the first patient was dosed in a Phase 1/2 clinical trial.

Key Points: 
  • Aleta Biotherapeutics (Aleta), a clinical stage, immuno-oncology company with a CAR T-Cell Engager (CTE) platform that enables cell cancer therapies to work more effectively, and Cancer Research UK’s Centre for Drug Development, today announce the first patient was dosed in a Phase 1/2 clinical trial.
  • This trial is evaluating the Company’s first-in-class biologic CAR T-Cell Engager, ALETA-001, for the treatment of patients with B-cell malignancies who are relapsed/refractory to CD19-targeting CAR T-cell therapy.
  • View the full release here: https://www.businesswire.com/news/home/20240221259676/en/
    Cancer Research UK’s Centre for Drug Development is sponsoring and conducting the Phase 1/2 clinical trial of ALETA-001, the lead agent in Aleta's portfolio.
  • Clinical evaluation of ALETA-001 is a key milestone toward a much-needed treatment option for the many cancer patients whose CD19-targeted CAR T-cell therapies ultimately stop working.

Health On Cloud Expands Global Presence with Innovative Metaverse Medical Platform

Retrieved on: 
Donnerstag, Dezember 28, 2023
Cloud, Cardiology, Multimedia, SHA, Developed country, Research, WHO, Amazon, ICT, Patient safety, Feasibility study, Education, CIO, Society, Cardiothoracic surgery, Genomics, Asan Medical Center, HOC, CLOUD, NHS foundation trust, University of Manchester, Pharmaceutical industry

SEOUL, South Korea, Dec. 28, 2023 /PRNewswire/ -- Health On Cloud, an innovator in advanced healthcare solutions, is excited to announce the global expansion of its revolutionary metaverse medical consultation platform, CURISALL, along with its medical education platform, MEDTIS.

Key Points: 
  • SEOUL, South Korea, Dec. 28, 2023 /PRNewswire/ -- Health On Cloud, an innovator in advanced healthcare solutions, is excited to announce the global expansion of its revolutionary metaverse medical consultation platform, CURISALL, along with its medical education platform, MEDTIS.
  • Health On Cloud is focused on deploying a globally connected Virtual University Hospital consisting of (i) Meta-Versity; and (ii) Cloud Hospital.
  • In line with WHO's vision, Health On Cloud envisions creating a world where no one is excluded from medical services.
  • Additionally, by collecting medical data through remote consultations, Health On Cloud aims to contribute to the latest advancements in healthcare technology.

Health On Cloud Expands Global Presence with Innovative Metaverse Medical Platform

Retrieved on: 
Donnerstag, Dezember 28, 2023
Cloud, Cardiology, SHA, Developed country, Research, WHO, Amazon, ICT, Patient safety, Feasibility study, Education, CIO, Society, Cardiothoracic surgery, Genomics, Asan Medical Center, HOC, CLOUD, NHS foundation trust, University of Manchester, Pharmaceutical industry

SEOUL, South Korea, Dec. 28, 2023 /PRNewswire/ -- Health On Cloud, an innovator in advanced healthcare solutions, is excited to announce the global expansion of its revolutionary metaverse medical consultation platform, CURISALL, along with its medical education platform, MEDTIS.

Key Points: 
  • SEOUL, South Korea, Dec. 28, 2023 /PRNewswire/ -- Health On Cloud, an innovator in advanced healthcare solutions, is excited to announce the global expansion of its revolutionary metaverse medical consultation platform, CURISALL, along with its medical education platform, MEDTIS.
  • Health On Cloud is focused on deploying a globally connected Virtual University Hospital consisting of (i) Meta-Versity; and (ii) Cloud Hospital.
  • In line with WHO's vision, Health On Cloud envisions creating a world where no one is excluded from medical services.
  • Additionally, by collecting medical data through remote consultations, Health On Cloud aims to contribute to the latest advancements in healthcare technology.

Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Retrieved on: 
Mittwoch, Dezember 13, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, NDA, Paclitaxel, Woman, Institute of Cancer Research, Research, Safety, Food, Avutometinib, Cancer, Letrozole, Disease, Verastem Oncology, Patient, Anastrozole, GOG, PFS, Consultant, RAMP, Breakthrough therapy, Part, FDA, NHS foundation trust, FRAME, ORR, The Institute, Ovarian cancer, FRCP, Doctor of Philosophy, Physician, Accelerated approval (FDA), Royal Marsden Hospital, Pharmaceutical industry, MBBS, Topotecan

“Patients and treating physicians have advocated for more research and development in support of LGSOC.

Key Points: 
  • “Patients and treating physicians have advocated for more research and development in support of LGSOC.
  • At Verastem Oncology, we are moving with urgency to offer a Phase 3 study specifically directed at this disease in an effort to address this need,” said Dan Paterson, President and Chief Executive Officer, Verastem Oncology.
  • RAMP 301 is a global trial with enrollment open in the U.S. and planned enrollment in Canada, the United Kingdom, Europe, Australia, and Korea.
  • Dr. Grisham and Dr. Banerjee are paid consultants for Verastem Oncology.